AU2008346823B2 - Inhibitors of cytochrome P450 - Google Patents

Inhibitors of cytochrome P450 Download PDF

Info

Publication number
AU2008346823B2
AU2008346823B2 AU2008346823A AU2008346823A AU2008346823B2 AU 2008346823 B2 AU2008346823 B2 AU 2008346823B2 AU 2008346823 A AU2008346823 A AU 2008346823A AU 2008346823 A AU2008346823 A AU 2008346823A AU 2008346823 B2 AU2008346823 B2 AU 2008346823B2
Authority
AU
Australia
Prior art keywords
formula
compounds
substituted
another embodiment
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008346823A
Other languages
English (en)
Other versions
AU2008346823A1 (en
Inventor
Manoj Desai
Hon Chung Hui
Hongtao Liu
Lianhong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2008346823A1 publication Critical patent/AU2008346823A1/en
Application granted granted Critical
Publication of AU2008346823B2 publication Critical patent/AU2008346823B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2008346823A 2008-01-04 2008-12-19 Inhibitors of cytochrome P450 Ceased AU2008346823B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1907908P 2008-01-04 2008-01-04
US61/019,079 2008-01-04
PCT/US2008/087821 WO2009088719A1 (en) 2008-01-04 2008-12-19 Inhibitors of cytochrome p450

Publications (2)

Publication Number Publication Date
AU2008346823A1 AU2008346823A1 (en) 2009-07-16
AU2008346823B2 true AU2008346823B2 (en) 2015-03-12

Family

ID=40380546

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008346823A Ceased AU2008346823B2 (en) 2008-01-04 2008-12-19 Inhibitors of cytochrome P450

Country Status (8)

Country Link
US (1) US8759379B2 (enExample)
EP (1) EP2231628B1 (enExample)
JP (2) JP5629585B2 (enExample)
AU (1) AU2008346823B2 (enExample)
CA (1) CA2710679A1 (enExample)
ES (1) ES2555209T3 (enExample)
PT (1) PT2231628E (enExample)
WO (1) WO2009088719A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
US8987313B2 (en) * 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2802315A1 (en) * 2012-01-12 2014-11-19 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
EP2938603A1 (en) * 2012-12-26 2015-11-04 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
CN105764533A (zh) * 2013-10-25 2016-07-13 儿童医疗中心有限公司 治疗或预防视网膜血管疾病的方法
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN105884826B (zh) * 2014-08-14 2018-01-19 赫斯（西安）生物科技有限公司 抗病毒药物
CN105669749B (zh) * 2014-08-14 2018-03-30 赫斯（西安）生物科技有限公司 抗病毒药物及组合物
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
EP3897854A2 (en) * 2018-12-21 2021-10-27 Aim Immunotech Inc. Compositions and methods for cancer therapy
WO2022061309A1 (en) * 2020-09-21 2022-03-24 Aim Immunotech Inc. Compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470816A (en) * 1993-07-08 1995-11-28 Nippon Paper Industries Co., Ltd. Thermal recording sheet
US5659045A (en) * 1989-05-23 1997-08-19 Abbott Laboratories Retroviral protease inhibiting compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
ES2123065T3 (es) * 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP1090914B1 (en) 1992-12-29 2003-01-02 Abbott Laboratories Retroviral protease inhibiting compounds
US5628072A (en) * 1994-06-20 1997-05-13 Sharp Plastics Manufacturing Ltd. Eye goggles with laterally adjustable eyepieces within goggles frame
DE4424828A1 (de) * 1994-07-14 1996-01-18 Thomae Gmbh Dr K Neue substituierte Arylsulfonamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
DE19653427A1 (de) * 1996-12-20 1998-07-02 Siemens Ag Kraftsensor
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
CA2371109C (en) 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations
BR0014602A (pt) 1999-10-06 2002-06-11 Tibotec Pharm Ltd Hexaidrofluoro'2,3-bifuran-3-il-n-{3'(1,3-benzodioxol- 5ilsulfonil)(isobutil)amino-1 -benzil-2-hidroxipropil}carbamato como inibidor da protease retroviral
US6448245B1 (en) * 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
AR050559A1 (es) * 2004-09-07 2006-11-01 Smithkline Beecham Corp Compuesto de diamina aciclica, composicion farmaceutica que lo comprende y su uso para la preparacion de dicha composicion
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
AR061838A1 (es) * 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
EP2118082B1 (en) * 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
KR20100040896A (ko) * 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659045A (en) * 1989-05-23 1997-08-19 Abbott Laboratories Retroviral protease inhibiting compounds
US5470816A (en) * 1993-07-08 1995-11-28 Nippon Paper Industries Co., Ltd. Thermal recording sheet

Also Published As

Publication number Publication date
US20090175820A1 (en) 2009-07-09
HK1148520A1 (zh) 2011-09-09
EP2231628B1 (en) 2015-10-28
EP2231628A1 (en) 2010-09-29
AU2008346823A1 (en) 2009-07-16
WO2009088719A1 (en) 2009-07-16
PT2231628E (pt) 2015-12-29
ES2555209T3 (es) 2015-12-29
JP5629585B2 (ja) 2014-11-19
US8759379B2 (en) 2014-06-24
JP2011508778A (ja) 2011-03-17
CA2710679A1 (en) 2009-07-16
JP2014169338A (ja) 2014-09-18

Similar Documents

Publication Publication Date Title
AU2008346823B2 (en) Inhibitors of cytochrome P450
AU2008218186B2 (en) Modulators of pharmacokinetic properties of therapeutics
EP2487165A1 (en) Modulators of pharmacokinetic properties of therapeutics
AU2008275744A1 (en) Modulators of pharmacokinetic properties of therapeutics
DK2487163T3 (en) Modulators of Pharmacokinetic properties terapeutikas
AU2022204390A1 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015204378B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015234299B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) Modulators of pharmacokinetic properties of therapeutics
HK1148520B (en) Inhibitors of cytochrome p450
HK40034020A (en) Modulators of pharmacokinetic properties of therapeutics
HK40112820A (en) Modulators of pharmacokinetic properties of therapeutics
HK40031994A (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768A1 (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768A (en) Modulators of pharmacokinetic properties of therapeutics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired